Algernon Pharmaceuticals Inc (AGNPF)

[ILuvblo2]

Md&a has some good tidbits.....

The development of the miniaturized breath test device is progressing well. Many proprietary components required for hand held breath testing, such as a high-voltage generator, non-radioactive ionization source, and proprietary detector, are being integrated with the novel FAIMS cell to provide the most technologically advanced FAIMS-based instrument in the world.

The Company has also identified two Requests for Proposals from the NIH in areas of interest and expertise within the Company and has drafted and submitted two separate NIH proposals in Q1 of 2017. The review process will occur this summer with award announcements soon after for potential funding in Q4 of 2017

The Company has made significant advancements in the design of our “V2” FAIMS prototype breath analyzer including reducing the size, weight and power requirements for our hand-held device design. The Company’s technical Team has been conducting design and performance testing of the new device in preparations for preclinical testing this summer and pilot clinical testing later this year. The Company has also engaged experts in the field of Product Development and Regulatory Affairs to determine the development and regulatory path to market for our FAIMS technology and have developed a commercialization plan. The Company has also been interviewing experts in the fields of diabetes, liver disease, infectious disease and hospital borne infections to identify opportunities for our technology for clinical use. The Company has also been exploring conducting a Voice of the Customer study to validate assumptions around the best indication for use for our first product to market




http://thecse.com/sites/default/files/BTHQ3MDAMay312017FINAL.pdf